Proliferative Diabetic Retinopathy (PDR) Market Report 2026

Proliferative Diabetic Retinopathy (PDR) Market Overview

• Proliferative Diabetic Retinopathy (PDR) market size has reached to $2.69 billion in 2025 • Expected to grow to $4.49 billion in 2030 at a compound annual growth rate (CAGR) of 11% • Growth Driver: Rising Diabetes Prevalence Boosts Growth In The Proliferative Diabetic Retinopathy (PDR) Market • Market Trend: Innovative Solutions For Early Detection And Improved Patient Outcomes • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Proliferative Diabetic Retinopathy (PDR) Market?

Proliferative diabetic retinopathy (PDR) refers to an advanced stage of diabetic eye disease characterized by the growth of abnormal blood vessels in the retina due to prolonged high blood sugar levels. These vessels can lead to retinal bleeding, scarring and vision impairment if left untreated, making regular eye examinations crucial for early detection and management. The main treatment types of proliferative diabetic retinopathy are anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery and vitrectomy. Intraocular steroids are medications administered directly into the eye to manage inflammation and treat conditions like diabetic macular edema or uveitis, helping reduce swelling and improve visual outcomes. The various mode of administration includes injectables, oral and others that are used by various applications such as hospitals, clinics and others.

What Is The Proliferative Diabetic Retinopathy (PDR) Market Growth Forecast?

The proliferative diabetic retinopathy (pdr) market size is expected to see rapid growth in the next few years. It will grow to $4.49 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing demand for long-acting injectable therapies, rising adoption of AI-based retinal diagnostics, expansion of outpatient ophthalmic procedures, growing focus on vision preservation strategies, increasing investment in diabetic eye disease management. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of advanced retinal imaging technologies, growing focus on early screening and diagnosis, expansion of minimally invasive surgical interventions, enhanced integration of multidisciplinary diabetes care.

Global Proliferative Diabetic Retinopathy (PDR) Market Segmentation

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy 2) By Mode of Administration: Injectables, Intravitreal Administration Focus, Other Mode Of Administrations 3) By Application: Hospitals, Clinics, Other Applications Subsegments: 1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab 2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide 3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation 4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

What Is The Driver Of The Proliferative Diabetic Retinopathy (PDR) Market?

The rising prevalence of diabetes is expected to propel the growth of the proliferative diabetic retinopathy (PDR) market going forward. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood. Diabetes is the leading cause of proliferative diabetic retinopathy disease, which can be treated by various methods that prevent further damage to the retina and preserve vision. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth highlights a concerning trend in this age group. The data reflects a rapid escalation in diabetes prevalence among younger populations. Therefore, the rising prevalence of diabetes drives the proliferative diabetic retinopathy (PDR) industry.

Key Players In The Global Proliferative Diabetic Retinopathy (PDR) Market

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Johnson And Johnson Limited, F Hoffmann La Roche Ltd, AbbVie Inc, Bayer AG, Novartis AG, Merck KGaA, Kubota Vision Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Mylan NV, Santen Pharmaceutical Co Ltd, Lupin Limited, Genentech Inc, Alcon Inc, Carl Zeiss Meditec AG, Topcon Corporation, Nidek Co Ltd, Bausch And Lomb Corporation, Heidelberg Engineering GmbH, Iridex Corporation, Lumenis Ltd, Optos plc, Zeiss Meditec India Pvt Ltd, Alimera Sciences Inc

Global Proliferative Diabetic Retinopathy (PDR) Market Trends and Insights

Major companies operating in the proliferative diabetic retinopathy (PDR) market are focusing on developing innovative solutions such as AI-based autonomous retinal screening systems and handheld fundus cameras to enhance early detection and improve patient outcomes. AI-based autonomous screening systems are designed to analyze retinal images without human intervention, providing rapid and accurate identification of diabetic retinopathy, while handheld fundus cameras allow portable and accessible retinal imaging. For instance, in April 2024, Optomed Plc, a Finland-based medical technology company, received U.S. Food and Drug Administration (FDA) clearance for its Optomed Aurora with AEYE, a handheld AI fundus camera capable of autonomously detecting referable diabetic retinopathy, thereby expanding the accessibility and efficiency of PDR screening beyond traditional clinical settings.

What Are Latest Mergers And Acquisitions In The Proliferative Diabetic Retinopathy (PDR) Market?

In July 2024, Merck and Co. Inc., a US-based healthcare company that develops and sells medicines, vaccines, and animal health products, acquired Eyebiotech Limited for a $3 billion amount. With this acquisition, Merck and Co., Inc. aims to enhance its ophthalmology pipeline by developing innovative therapies for sight-threatening retinal diseases and addressing significant unmet medical needs in this area. Eyebiotech Limited is a UK-based biotechnology company that focuses on developing therapies for proliferative diabetic retinopathy to combat abnormal retinal blood vessel growth.

Regional Outlook

North America was the largest region in the proliferative diabetic retinopathy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Proliferative Diabetic Retinopathy (PDR) Market?

The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Proliferative Diabetic Retinopathy (PDR) Market Report 2026?

The proliferative diabetic retinopathy (pdr) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the proliferative diabetic retinopathy (pdr) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.